New pill aims to keep aggressive neuroendocrine cancer at bay
NCT ID NCT06926634
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether the drug zanzalintinib, taken as a maintenance therapy after initial chemotherapy, can help delay cancer progression in people with high-grade neuroendocrine neoplasms. About 32 participants will receive the drug and be monitored for how long their cancer stays under control. The goal is to see if this approach extends the time before the cancer worsens.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zanzalintinib
- What this could lead to
- If successful, this could provide a new maintenance option to delay cancer growth after initial chemotherapy for patients with high-grade neuroendocrine tumors.
- What could go wrong
- This is a small early-phase trial with only 32 participants, so results may not apply broadly. The drug may not improve survival and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic - Rochester
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.